Features of patients with AA with somatic mutations and wild-type, based on disease duration
| Disease duration* . | No. of patients . | Mutations (n = 29) . | Wild-type (n = 131) . | P . |
|---|---|---|---|---|
| <6 months | 63 | 9 | 54 | |
| Transformation to MDS | 3 | 3 | <.03 | |
| Median mutant allele burden <10% | 7 | NA | ||
| >6 months | 87 | 20 | 67 | |
| Transformation to MDS | 8 | 3 | <.0002 | |
| Median mutant allele burden <10% | 4 | NA |
| Disease duration* . | No. of patients . | Mutations (n = 29) . | Wild-type (n = 131) . | P . |
|---|---|---|---|---|
| <6 months | 63 | 9 | 54 | |
| Transformation to MDS | 3 | 3 | <.03 | |
| Median mutant allele burden <10% | 7 | NA | ||
| >6 months | 87 | 20 | 67 | |
| Transformation to MDS | 8 | 3 | <.0002 | |
| Median mutant allele burden <10% | 4 | NA |
NA, not applicable.
Time interval from initial diagnosis of AA (first presentation) to sampling date for patients with median mutant allele burden (proportion of sequence reads harboring mutation) less than 10% (ie, subclonal mutations). The data include both patients evaluated in the initial cohort and in the second focused cohort; the breakdown for second focused cohort is provided in supplemental Table 6.